A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials
From MaRDI portal
Publication:6071311
DOI10.1002/bimj.201900306zbMath1523.62206OpenAlexW3089368515WikidataQ100418332 ScholiaQ100418332MaRDI QIDQ6071311
Unnamed Author, Takeshi Emura, Virginie Rondeau
Publication date: 23 November 2023
Published in: Biometrical Journal (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1002/bimj.201900306
numerical integrationsurrogate endpointjoint frailty-copula modelmeta-analysis of clinical trialsone-step validation method
Related Items (1)
Cites Work
- Unnamed Item
- Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
- Fast fitting of joint models for longitudinal and event time data using a pseudo-adaptive Gaussian quadrature rule
- An introduction to copulas.
- Maximum penalized likelihood estimation in a Gamma-frailty model
- Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
- Meta-analysis of individual patient data with semi-competing risks under the Weibull joint frailty-copula model
- The frailty model.
- An Algorithm for Least-Squares Estimation of Nonlinear Parameters
- Fast Computation of Fully Automated Log-Density and Log-Hazard Estimators
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- A Penalized Likelihood Approach for Arbitrarily Censored and Truncated Data: Application to Age-Specific Incidence of Dementia
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- A Version of the EM Algorithm for Proportional Hazard Model with Random Effects
- Extending the Archimedean Copula Methodology to Model Multivariate Survival Data Grouped in Clusters of Variable Size
- Choice between Semi‐parametric Estimators of Markov and Non‐Markov Multi‐state Models from Coarsened Observations
This page was built for publication: A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials